Rescriptor (Delavirdine Mesylate) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

February 10, 2012

Rescriptor

Human Immunodeficiency Virus »

What is the history of HIV, and when was HIV discovered?

The history of the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) dates back to 1981, when homosexual men with symptoms of a disease that now are considered typical of AIDS were first described in Los Angeles and New York. The men had an unusual type of lung infection (pneumonia) called Pneumocystis carinii (now known as Pneumocystis jiroveci) pneumonia (PCP) and rare skin tumors called Kaposi's sarcomas. The patients were noted to have a severe reduction in a type of cell in the blood (CD4 cells) that is an important part of the immune system. These cells, often referred to as T cells, help the body fight infections. Shortly thereafter, this disease was recognized throughout the United States, Western Europe, and Africa. In 1983, researchers in the United States and France described the virus that causes AIDS, now known as HIV, belonging to t...

Read the Human Immunodeficiency Virus article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
next »

Rescriptor User Reviews >>

Rescriptor

HIV AIDS Myths and Facts Slideshow Pictures

Take the HIV/AIDS Quiz

AIDS Retrospective Slideshow Pictures

font size

RESCRIPTOR®
(delavirdine mesylate) Tablets

DRUG DESCRIPTION

RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor of the human immuno deficiency virus type 1 (HIV-1). The chemical name of delavirdine mesylate is piperazine, 1-[3-[(1-methyl-ethyl) amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl) amino]-1H-indol-2-yl]carbonyl]-,monomethane sulfonate. Its molecular formula is C₂₂H₂₈N₆O₃S•E CH₄O₃S, and itsmolecular weight is 552.68. The structural formula is:

RESCRIPTOR (delavirdine mesylate) Structural Formula Illustration

Delavirdine mesylate is an odorless white-to-tan crystalline powder. The aqueous solubility of delavirdine free base at 23° C is 2942 µg/mL at pH 1.0, 295 µg/mL at pH2.0, and 0.81 µg/mL at pH 7.4.

Each RESCRIPTOR (delavirdine mesylate) Tablet, for oral administration, contains 100 or 200 mg of delavirdine mesylate (hence forth referred to as delavirdine). Inactive ingredients consistof lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and carnauba wax. In addition, the 100 mg tablet contains Opadry White YS-1-7000-E and the 200 mg tablet contains hypromellose, Opadry White YS-1-18202-A and Pharmaceutical Ink Black.

What are the possible side effects of delavirdine (Rescriptor)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
easy bruising or bleeding, unusual weakness;
fever, chills, body aches, flu symptoms; or
any other signs of new infection.

Less serious side effects may...

Read All Potential Side Effects and See Pictures of Rescriptor »

What are the precautions when taking delavirdine mesylate (Rescriptor)?

Before taking delavirdine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver problems.

To decrease your risk of spreading HIV disease to others, always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity. Consult your doctor or pharmacist for more details.

During pregnancy, this medication should be used only when clearly needed. However, HIV medicines are now usually given to pregnant women with HIV. Treatment has been shown to...

Read All Potential Precautions of Rescriptor »

Last reviewed on RxList: 11/25/2008
This monograph has been modified to include the generic and brand name in many instances.